The oral tablet formulation of butylscopolamine, which is available without prescription, is commonly used by trainers of racing greyhounds to treat functional urethral obstruction. As medication control of butylscopolamine is therefore required for such use to ensure the integrity of greyhound racing, an administration study was performed in six greyhounds to determine the pharmacokinetics of orally administered butylscopolamine. A single dose of one 10 mg butylscopolamine tablet was administered orally to simulate this use in greyhound racing. Blood, urine and faeces were collected at regular intervals from the greyhounds for up to 9 days and butylscopolamine concentrations determined. There was some, but very limited, absorption of butylscopolamine, with rapid elimination from plasma with a mean halflife of 2 hr. Urine concentrations initially declined in a similar manner to the plasma pharmacokinetics but then entered a much longer half-life of approximately 50 hr.
| INTRODUC TI ON
Butylscopolamine is an antimuscarinic quaternary ammonium derivative of scopolamine used for relieving spasm of the smooth muscle of the digestive (Tytgat, 2007) and urinary systems (Papadopoulos et al., 2014) . It is available for medical and veterinary use in injectable formulations, both alone but also in combination with the non steroidal anti-inflammatory drug metamizole, and in tablet form, and is commonly referred to under its original trade name Buscopan ® .
Greyhound trainers commonly report that some racing greyhounds "tie-up" around racing, this being associated with excitement and characterized by full or partial inability to urinate. This condition has not been well defined (Van Meeuwen, 2009 ) but is likely to be a functional obstruction such as that defined as detrusor-urethral dyssynergia, with this considered to result from over discharge of acetylcholine to the urethral sphincter leading to contraction of the detrusor muscles (Espineira & Nickel, 1997; Tytgat, 2007) .
Butylscopolamine is available as a tablet for oral administration for human medical use without prescription in the United Kingdom, Ireland and Australia, and related to this availability is commonly used by trainers symptomatically to treat full or partial inability to urinate in racing greyhounds.
The aim of this study was to characterize the analytical detection, the plasma and the urinary pharmacokinetics of butylscopolamine given orally to greyhounds at the dose and formulation commonly the final concentration was adjusted to express the amount in dry matter.
The urine and plasma methods produced a lower limit of quantification (LLOQ) of 10 and 50 pg/mL, respectively, and they were shown to be accurate and reproducible with acceptable interbatch variability of precision and accuracy. The precision of the urine method was demonstrated to be within ±19.4% at LLOQ and within ±12.3% at higher QC concentrations (30, 2,500 and 4,500 pg/ml), whilst the precision of the plasma method was within ±8.2% at all QC concentrations (50, 100, 10,000 and 16,000 pg/ml). The accuracy of the urine method was within ±9.8% at all QC concentrations, whilst the accuracy of the plasma method was within ±13.0% at all QC concentrations. Urine QC samples diluted 1-in-100 for urine samples also produced acceptable results with precision within ±5.6% and accuracy within ±8.2%.
The LLOQ of faecal method was 0.2 ng/g. The precision of the method in a single batch was within ±6.9% at QC concentrations of 0.2, 20 and 40 ng/g, whilst the accuracy was within ±11.9% at these QC concentrations. Chromatographic separation was achieved on an Acquity HSS T3 (100 mm × 2.1 mm, 1.8 μm) column using 0.1% formic acid in methanol (A) and 0.1% formic acid in water (B) as mobile phases. Gradient was operated at 50°C and at a flow rate of 0.4 ml/min. It was started at 10% organic for 0.5 min followed by increase to 99.9% A at 3 min.
This was held for 1 min before resuming the initial conditions and re-equilibrating.
Pharmacokinetic parameters were estimated using noncompartmental analysis with Phoenix WinNonlin 7.0 (Pharsight Corporation, Cary, NC). The area under the plasma curve to infinity (AUC 0-inf ) was calculated using the log-linear trapezoidal rule with the AUC for the last time point to infinity determined from the final plasma concentration divided by the elimination rate constant for the terminal phase.
| RE SULTS
Following oral administration to six greyhounds of butylscopolamine bromide plasma pharmacokinetic parameters for are summarized in Table 1 , mean plasma and urine concentrations of butylscopolamine are illustrated in Figure 1 , and concentrations of butylscopolamine in faeces given in Table 2 .
| D ISCUSS I ON
Greyhound trainers commonly use butylscopolamine tablets bought without prescription when racing greyhounds "tie-up" around racing.
The rationale for this use is questionable given the poor oral absorption of quaternary ammonium compounds (Leusch, Eichhorn, Müller, & Rominger, 2001; Tytgat, 2007) and reports of its limited efficacy in reducing urethral obstruction or pressure in dogs (Murakami et al., 2000; Papadopoulos et al., 2014) . No reported detection time studies for butylscopolamine in dogs have been found, and there is very limited pharmacokinetic data published (Tytgat, 2007) Butylscopolamine entering the duodenum, 10 mg in 500 ml of fluid, will lead to an approximate concentration of 20 μg/ml. If just 5% of butylscopolamine is absorbed, then the initial concentration that the plexus will observe in the gut is approximately 1,000 ng/ ml. This value is similar to the M 3 receptor potency determined for guinea pig (Tytgat, 2007) and indicates an antispasmodic effect on the gut. However, 1,000 ng/ml is massively higher than the peak plasma concentrations observed from this greyhound oral administration study which are in the low ng/ml range (Figure 1 (Gibaldi & Perrier, 1982) . This study confirms the very low oral bioavailability observed for butylscopolamine in previous animal studies and no systemic antimuscarinic effect. This, coupled with limited efficacy, would indicate its use for functional urethral obstruction such as that defined as detrusor-urethral dyssynergia, is unjustified.
Butylscopolamine urine concentrations peak at 4 hr before initially declining in a similar manner to the plasma pharmacokinetics (Figure 1 ). The ratio of urine to plasma butylscopolamine concentrations between 4 hours (peak urine concentration) and 12 hr is very large with a value of approximately 1,000. A very large ratio of this magnitude indicates that butylscopolamine undergoes rapid renal clearance that approaches renal blood flow in the dog. This seems likely as butylscopolamine is mainly excreted in the urine after parenteral Note. SAT: saturation of detection despite 1/1,000 dilution; ND: not detected, 0.02 ng/ml is the lower limit of quantification. Dogs are numbered in order of the time of drug administration and this administration time was identical for Dogs 5 and 6.
TA B L E 2 Concentrations of butylscopolamine in faeces, in ng/g dry matter, after following a single oral 10 mg dose to six greyhounds administration (Committee For Veterinary Medicinal Products, 1997).
Moreover, tiotropium (another quaternary ammonium drug) undergoes renal clearance that exceeds creatinine clearance indicating active secretion into the urine (Durham, 2004) . After 2 days, the urine concentrations enter a much longer half-life of approximately 50 hr (Figure 1 ). It is not clear what is driving this long terminal phase in the urine but may be due to either some recirculation via the enterohepatic system or a small amount of the drug residing in a specific tissue leading to a large terminal volume of distribution. Similar properties of other quaternary ammonium compounds suggest binding in tissues does occur (Leusch et al., 2001 ).
Medication control rules for animals in competitions rely either on an effect on body systems, a direct or indirect effect on performance, on relate the substance to its presence on a defined list.
Medication control can be managed by the use of screening limits, based on an understanding of the levels of a drug that are no longer therapeutically effective (Morris, 2015) . This study also indicates that orally administered butylscopolamine could be a rational therapy for relieving spasm of the smooth muscle of the digestive tract.
As such medication control is required for orally administered butylscopolamine in racing greyhounds, based on measures of blood or urinary concentrations. The total gastrointestinal tract transit time in dogs ranges from 22 to 57 hr (Boillat, Gaschen, & Hosgood, 2010) . Faecal concentrations of butylscopolamine fall to ng/ml levels between 48 and 120 hr after oral administration (Table 2) , and gut receptor potency (Tytgat, 2007 ) is a thousand times higher. This would indicate a urine screening level in the range of 100-10 pg/ml (Figure 1 ) should be the starting point for regulatory considerations to control the use of orally administered butylscopolamine in racing greyhounds. Such screening limits are set independently by regulatory authorities, guided by scientific information and analytical considerations (Morris, 2015) .
It is concluded that the use of orally administered butylscopolamine for functional urethral obstruction in greyhounds is unjustified, and that medication control of its antispasmodic effect on the digestive tract will be possible by setting a urinary screening limit based on the urinary and faecal drug levels as determined in this study.
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